Form 424B5 - Prospectus [Rule 424(b)(5)]:
SEC Accession No. 0001193125-24-033870
Filing Date
2024-02-13
Accepted
2024-02-13 16:46:27
Documents
3

Document Format Files

Seq Description Document Type Size
1 424B5 d779512d424b5.htm 424B5 493498
2 GRAPHIC g779512g00p78.jpg GRAPHIC 53908
3 GRAPHIC g779512g01a04.jpg GRAPHIC 53908
  Complete submission text file 0001193125-24-033870.txt   629980
Mailing Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004
Business Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004 844-511-9056
Larimar Therapeutics, Inc. (Filer) CIK: 0001374690 (see all company filings)

EIN.: 203857670 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 424B5 | Act: 33 | File No.: 333-268312 | Film No.: 24626918
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)